Ress Anna Lena, Stiegelbauer Verena, Winter Elke, Schwarzenbacher Daniela, Kiesslich Tobias, Lax Sigurd, Jahn Stefan, Deutsch Alexander, Bauernhofer Thomas, Ling Hui, Samonigg Hellmut, Gerger Armin, Hoefler Gerald, Pichler Martin
Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.
Institute of Pathology, Medical University of Graz (MUG), Graz, Austria.
Mol Carcinog. 2015 Nov;54(11):1442-50. doi: 10.1002/mc.22218. Epub 2014 Sep 25.
Expression of miR-96-5p is frequently altered in various types of cancer and the KRAS oncogene has been identified as one of its potential targets. However, the biological role of miR-96-5p expression in colorectal cancer (CRC) and its ability to predict the clinical course of patients have not been investigated yet. In this study, we explored miR-96-5p expression in 80 CRC patients and evaluated the impact on clinical outcome by Kaplan-Meier curves and multivariate Cox proportional models. In vitro miR-96-5p inhibition and overexpression were performed in CRC cells and the effects on cellular growth, anchorage-independent growth, apoptosis, and epithelial-mesenchymal transition (EMT)-related gene expression were explored. Low miR-96-5p expression levels in tumor tissue were associated with distant metastasis (P = 0.025) and multivariate Cox regression analysis identified low levels of miR-96-5p as an independent prognostic factor with respect to cancer-specific survival (hazard ratio = 1.78, 95%CI = 1.03-3.03, P < 0.038). In vitro overexpression of miR-96-5p led to a reduced cellular growth rate (P < 0.05), reduced colonies in soft agar (P < 0.05), corroborated by a decreased cyclin D1 and increased p27-CDKN1A expression (P < 0.05). Forced expression of miR-96-5p in CRC cells entailed no effects on apoptosis or EMT-related genes but decreased the expression levels of the KRAS oncogene (P < 0.05). Despite regulating KRAS expression, there was no significant association in miR-96-5p expression levels and response rates to EGFR-targeting agents. In conclusion, our data suggest that miR-96-5p influences cellular growth of CRC cells and low expression of miR-96-5p seems to be associated with poor clinical outcome in CRC patients.
miR-96-5p的表达在多种类型癌症中常发生改变,KRAS癌基因已被确定为其潜在靶点之一。然而,miR-96-5p表达在结直肠癌(CRC)中的生物学作用及其预测患者临床病程的能力尚未得到研究。在本研究中,我们检测了80例CRC患者的miR-96-5p表达,并通过Kaplan-Meier曲线和多变量Cox比例模型评估其对临床结局的影响。在CRC细胞中进行了体外miR-96-5p抑制和过表达实验,并探讨了其对细胞生长、非锚定依赖性生长、凋亡以及上皮-间质转化(EMT)相关基因表达的影响。肿瘤组织中miR-96-5p低表达水平与远处转移相关(P = 0.025),多变量Cox回归分析确定miR-96-5p低水平是癌症特异性生存的独立预后因素(风险比= 1.78,95%CI = 1.03 - 3.03,P < 0.038)。体外miR-96-5p过表达导致细胞生长速率降低(P < 0.05),软琼脂中集落减少(P < 0.05),细胞周期蛋白D1表达降低和p27 - CDK N1A表达增加也证实了这一点(P < 0.05)。在CRC细胞中强制表达miR-96-5p对凋亡或EMT相关基因无影响,但降低了KRAS癌基因的表达水平(P < 0.05)。尽管miR-96-5p调节KRAS表达,但其表达水平与EGFR靶向药物的反应率之间无显著关联。总之,我们的数据表明miR-96-5p影响CRC细胞的生长,miR-96-5p低表达似乎与CRC患者不良临床结局相关。